Justin Cousins

UTAS Home Mr Justin Cousins

Justin Cousins

Lecturer in Pharmacy Practice

Room 3010 , Pharmacy

+61 3 6226 1005 (phone)

+61 3 6226 2870 (fax)

Justin is a lecturer in pharmacy practice. He has a background in a variety of pharmacy areas within Australia and abroad. His experience includes: community pharmacy, medication management, hospital pharmacy research and academia.


Justin commenced his career as a community pharmacist. In this role he worked in a variety of locations and settings within Tasmania, far north Queensland and Dublin, Ireland. After returning to Tasmania, Justin began providing medication reviews and commenced tutoring roles at the University of Tasmania. He is currently undertaking a PhD researching adverse drug reactions in older people while coordinating the year 4 pharmacy practice units. He continues to work as a pharmacist in consultant and advisory roles.

Career summary


  • BPharm (1st Class Hons), Prescribing of Psychotropic Medication for Residential Aged Care Facility residents with dementia – A General Practitioner Survey, University of Tasmania, Australia, 2015
  • Bachelor of Pharmacy, University of Tasmania, Australia, 1999


Professional practice

  • Pharmaceutical Society of Australia
  • Australian Association of Consultant Pharmacists
  • Pharmaceutical Defence Limited – Local advisory committee member

Administrative expertise

Justin was a director of a consultant pharmacy business. In this business he had roles coordinating pharmacist services.


Pharmacy Practice, Therapeutics in Practice, Pharmacotherapeutics

Teaching responsibility

Justin is the unit coordinator for CSA457 Pharmacy Skills in Practice 4a, and CSA430 Pharmacy Practice

View more on Mr Justin Cousins in WARP


  • Adverse Drug Reactions
  • Medication management
  • Medication in older people
  • Residential aged care

Research Themes

Justin’s research aligns with the University’s research theme of Better Health through researching medication safety in older people. His PhD is investigating adverse drug reactions in older people following hospital discharge.

Current projects

Justin’s current research is focusing on adverse drug reactions in older people in both the aged care setting and after hospital discharge.

Fields of Research

  • Clinical pharmacy and pharmacy practice (321403)
  • Clinical pharmacology and therapeutics (321402)
  • Rheumatology and arthritis (320223)
  • Aged health care (420301)
  • Preventative health care (420605)

Research Objectives

  • Evaluation of health and support services (200299)
  • Health related to ageing (200502)
  • Clinical health (200199)
  • Evaluation of health outcomes (200202)
  • Expanding knowledge in the biomedical and clinical sciences (280103)
  • Health education and promotion (200203)
  • Allied health therapies (excl. mental health services) (200301)
  • Expanding knowledge in the health sciences (280112)


Total publications


Journal Article

(7 outputs)
2022Davey BJ, Lindsay D, Cousins J, Glass BD, 'Scoping the required business management skills for community pharmacy: perspectives of pharmacy stakeholders and pharmacy students', Currents in Pharmacy Teaching and Learning, 14, (7) pp. 909-928. ISSN 1877-1297 (2022) [Refereed Article]

DOI: 10.1016/j.cptl.2022.07.002 [eCite] [Details]


2022Roughead EE, Pratt NL, Parfitt G, Rowett D, Kalisch-Ellett LM, et al., 'Effect of an ongoing pharmacist service to reduce medicine-induced deterioration and adverse reactions in aged-care facilities (nursing homes): a multicentre, randomised controlled trial (the ReMInDAR trial)', Age and Ageing, 51, (4) Article afac092. ISSN 0002-0729 (2022) [Refereed Article]

DOI: 10.1093/ageing/afac092 [eCite] [Details]

Citations: Web of Science - 1

Co-authors: Bereznicki L; Williams M


2021Cousins J, Parameswaran Nair N, Curtain C, Bereznicki B, Wilson K, et al., 'Preventing adverse drug reactions after hospital discharge (PADR-AD): Protocol for a randomised-controlled trial in older people', Research in Social and Administrative Pharmacy ISSN 1934-8150 (2021) [Refereed Article]

DOI: 10.1016/j.sapharm.2021.09.007 [eCite] [Details]

Co-authors: Parameswaran Nair N; Curtain C; Bereznicki B; Wilson K; Bereznicki L


2020Curtain CM, Chang JY, Cousins J, Parameswaran Nair N, Bereznicki B, et al., 'Medication regimen complexity index prediction of adverse drug reaction-related hospital admissions', The Annals of Pharmacotherapy, 54, (10) Article 996-1000. ISSN 1060-0280 (2020) [Refereed Article]

DOI: 10.1177/1060028020919188 [eCite] [Details]

Citations: Scopus - 3Web of Science - 3

Co-authors: Curtain CM; Parameswaran Nair N; Bereznicki B; Bereznicki L


2020Lim R, Bereznicki LR, Corlis M, Kalisch Ellet LM, Kang AC, et al., 'Reducing medicine-induced deterioration and adverse reactions (ReMInDAR) trial: study protocol for a randomised controlled trial in residential aged-care facilities assessing frailty as the primary outcome', BMJ open, 10, (4) Article e032851. ISSN 2044-6055 (2020) [Refereed Article]

DOI: 10.1136/bmjopen-2019-032851 [eCite] [Details]

Citations: Scopus - 3Web of Science - 3

Co-authors: Bereznicki LR; Williams M


2017Cousins JM, Bereznicki LRE, Cooling NB, Peterson GM, 'Prescribing of psychotropic medication for nursing home residents with dementia: a general practitioner survey', Clinical Interventions in Aging, 12 pp. 1573-1578. ISSN 1178-1998 (2017) [Refereed Article]

DOI: 10.2147/CIA.S146613 [eCite] [Details]

Citations: Scopus - 12Web of Science - 11

Co-authors: Bereznicki LRE; Cooling NB; Peterson GM


2016Curtain CM, Williams M, Cousins JM, Peterson GM, Winzenberg T, 'Vitamin D supplementation in Tasmanian nursing home residents', Drugs and Aging, 33, (10) pp. 747-754. ISSN 1170-229X (2016) [Refereed Article]

DOI: 10.1007/s40266-016-0398-6 [eCite] [Details]

Citations: Scopus - 6Web of Science - 5

Co-authors: Curtain CM; Williams M; Peterson GM; Winzenberg T


Conference Publication

(5 outputs)
2021Cousins J, Parameswaran Nair N, Curtain CM, Bereznicki BJ, Wilson KM, et al., 'Preventing adverse drug reactions after discharge: protocol for a randomised controlled trial in older people', APSA 2021 Annual Conference Book of Oral Abstracts, 06-08 December, online, pp. 251. (2021) [Conference Extract]

[eCite] [Details]

Co-authors: Parameswaran Nair N; Curtain CM; Bereznicki BJ; Wilson KM; Bereznicki LRE

2018Thompson A, Cousins J, Curtain C, Williams M, 'Magnesium deficiency with proton pump inhibitors: is it more common than we thought?', NPS MedicineWise Conference, National Medicine Symposium (NMS), 30 May - 1 June 2018, Canberra, Australia (2018) [Conference Extract]

[eCite] [Details]

Co-authors: Thompson A; Curtain C; Williams M

2017Toh L, Thompson AJ, Shah A, Cousins JM, Jackson S, et al., ''Good prescribing is a bit like good driving; everybody thinks they're a good driver.' An exploratory study on the barriers and facilitators to using quality prescribing indicators (QPIs) in general practice', APSA-ASCEPT Joint Meeting, 5 - 8 December 2017, Brisbane, Australia (2017) [Conference Extract]

[eCite] [Details]

Co-authors: Toh L; Thompson AJ; Jackson S; Cooling NB; Peterson GM

2016Thompson AJ, Cousins JM, Hoyle D, Wimmer BC, 'Polypharmacy, hyperpolypharmacy and age - the implications for medication management services', National Medicines Symposium, 19-20 May, 2016, Canberra, Australia (2016) [Conference Extract]

[eCite] [Details]

Co-authors: Thompson AJ; Hoyle D; Wimmer BC

2015Williams Mackenzie, Cousins JM, Curtain CM, Peterson GM, Winzenberg TM, 'Preliminary results of Vitamin D supplementation in residents of aged care facilities', APSA ASCEPT Conference, 29 November - 2 December, 2015, Hobart, Tasmania (2015) [Conference Extract]

[eCite] [Details]

Co-authors: Williams Mackenzie; Curtain CM; Peterson GM; Winzenberg TM

Grants & Funding

Funding Summary

Number of grants


Total funding



Preventing Adverse Drug Reactions in the Elderly (2019 - 2022)$274,000
Based on our prospective adverse drug reaction (ADR) registry:1*15% of medical admissions to Tasmanian public hospitals in elderly patients were ADR-related,*89% were preventable,*17% patients had a repeat ADR within 12 months, and*One third of patients with repeat ADRs experienced the same ADR caused by the same medications.From this clinical registry, we developed and validated an ADR risk prediction score (PADR-EC).2We hypothesise that ADR risk stratification during hospitalisation and communication of this risk, together with recommendations that target the specific risk factors identified, to GPs at discharge will reduce the risk of ADR-related hospitalisation.Design: A randomised controlled trial (RCT) at the Royal Hobart Hospital, the major public hospital in Tasmania.Population: Over 12-months, 1000 patients ≥65 years with unplanned admissions to medical wards will be recruited and randomly allocated to intervention or control groups.Intervention: A researcher will perform an ADR risk assessment using the PADR-EC Score,2 which is the sum of points assigned to 5 independent predictors of ADR-related hospitalisation. Based on the PADR-EC Score and the specific risk factors identified, recommendations to reduce the risk of ADRs will be determined.Recommendations will relate to:*post-discharge medication management services, *monitoring of specific parameters/medications, and *de-prescribing strategies.The PADR-EC Score and recommendations will be communicated to the patient and clinical team during hospitalisation, and the patient's GP, alongside the usual information, in the electronic discharge summary. Control: Usual hospital care, with GPs receiving the standard discharge summary.Follow up: All participants will be followed by the research team for 12-months to identify ADRs (including their management and outcome) and health services received.Outcomes: ADR-related hospitalisation (primary); ADRs requiring hospital treatment, change in therapy or specific treatment (secondary). The study will be powered to detect a 5% difference in the primary outcome
HCF Health and Medical Research Foundation ($274,000)
Grant-Health Services Research Program (HCF)
Administered By
University of Tasmania
Research Team
Bereznicki LRE; Curtain CM; Bereznicki BJ; Cousins JM; Connolly M; Adamczewski B; McKenzie D; Simpson T; Barratt A; Webber E; Parameswaran Nair N
2019 - 2022
ReMInDAR Trial Reducing Medicine Induced Deterioration and Adverse Reactions Trial (2018 - 2020)$2,847,927
This randomised controlled trial will assess a pharmacist led intervention to reduce medicine induced deterioration and adverse reactions. Medicine induced deterioration encompasses the spectrum of side effects that are frequently not recognised as medication related but are misattributed as geriatric syndromes, frailty or changes due to aging. The aim of the service is to enable early identification of signs and symptoms of medicine- induced deterioration so that worsening frailty and subsequent adverse events, such as injurious falls, fractures and delirium are prevented. In implementing the service, the pharmacist will use a suite of validated tools to assist in the detection of signs and symptoms of medicine-induced deterioration. The validated tools will encompass assessments to monitor changes in cognition, change in 24-hour movement behavior, including sleep, as well as grip strength. In addition, pharmacists will assess the potential for adverse medicine events via review of the resident care assessment record and through patient or carer reported changes in health since the medicine regimen was changed. The pharmacist service will be compared with usual care. The trial, involving 500 patients will take place in aged-care facilities in South Australia and Tasmania. Evaluation will encompass health program, clinical and economic evaluation. The expected clinical outcome is a reduction in medication-induced deterioration, as measured by change in frailty score. Adverse events will be measured as a secondary outcome. The cost- effectiveness evaluation will assess cost per adverse event avoided.
Department of Health (Cth) ($2,847,927)
Pharmacy Trial Program (Tranche 2)
Administered By
University of Tasmania
Research Team
Bereznicki LRE; Roughead L; Pratt N; Parfitt G; Cousins JM; Williams M
2018 - 2020